© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Back in the early 1970s, Japanese microbiologist Akira Endo and his team at Sankyo Company began rooting through thousands of fungi samples, searching for compounds that could clamp down on cholesterol production. Their hunt paid off with the discovery of a molecule made by Penicillium citrinum. They called it mevastatin, the first natural statin. Mevastatin blocked HMG-CoA reductase, an enzyme at the crossroads of cholesterol biosynthesis. Pharmaceutical history took a turn with this discovery. Difficulties with toxicity and animal testing held up development, but the groundwork was in place. Mevastatin’s story opened the gate for molecules like lovastatin and the whole cholesterol-lowering drug revolution. The chase for effective, safe cholesterol management got its big push from a humble mold.
Mevastatin is a fungal secondary metabolite. It takes the form of a white or off-white crystalline powder, with a notably bitter taste if you ever catch a whiff. Structurally, it looks like a compact, tightly-wound molecule—part polyketide, part sophisticated enzyme inhibitor. Chemists usually assign it to the statin class, which puts it in the company of blockbuster drugs. Mevastatin’s main utility isn’t just as a cholesterol drug; it’s also a chemical tool for biochemists who want to pick apart how cells make lipids. Industrial labs prize it for its selectivity against HMG-CoA reductase. Its place in the pharma supply chain is mainly as a reference compound and research control rather than a mass-market medication.
This compound typically has a molecular formula of C23H34O5, clocking in at a molecular weight close to 390 Da. Chemists note a melting point of about 166°C. Mevastatin dissolves well in organic solvents like ethanol, chloroform, and methanol, but shrugs off water. It holds a handful of chiral centers, creating the possibility for stereochemical variants. The hydroxyl and ester groups peppered across its structure participate in hydrogen bonding, affecting how it interacts in the body. Its logP (partition coefficient) signals a relatively hydrophobic nature, suggesting it crosses cell membranes with ease, a feature that helps it slip into its biological target’s binding pocket.
Suppliers selling mevastatin for research typically set a purity threshold over 98%, confirmed by HPLC and NMR. Each batch comes with a certificate of analysis outlining appearance, assay, melting range, and residual solvent levels. You’ll see vials labeled with the IUPAC name: (3R,5R,6E)-7-[2-(4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl]-3,5-dihydroxyhept-6-enoic acid lactone. There are also hazard warnings: “harmful if swallowed,” “may cause respiratory irritation,” and advice to wear gloves and goggles. MSDS sheets emphasize proper ventilation and disposal by incineration. Storage below -20°C in the dark slows breakdown and protects sensitive chemical groups. This description shows how managing a fine chemical involves as much care as the research itself.
Mevastatin production revolves around fermenting fungi like Penicillium citrinum under controlled conditions. Usually, fermenters pack in a starchy medium and monitor pH, temperature, and oxygen to keep the mold happy. After the fermentation runs its course, technicians filter out solids, extract the broth with organic solvents, and concentrate the product. Purification mostly depends on repeated chromatography, taking advantage of mevastatin’s unique polarity and molecular size. Sometimes, chemical conversion steps turn the product from its acid to lactone form, or vice versa, because researchers value each for different studies. Each harvest keeps the pipeline of research-grade material flowing, and the steps echo the painstaking attention that pharmaceutical manufacturing deserves.
Mevastatin’s chemistry centers on its lactone ring and hydroxyl groups. There’s a routine conversion between the open acid and closed lactone forms under mild basic or acidic conditions. Chemists sometimes tack on additional groups by acylation or alkylation at the 3- or 5-position, changing the molecule’s binding or breakdown in biological systems. Early experiments involved swapping or masking functional groups to produce analogs that held promise for lower toxicity or improved activity—some resulting in statin drugs that followed in mevastatin’s scientific footsteps. The molecule’s reactivity makes it a versatile template for new discoveries in natural product medicinal chemistry.
Mevastatin goes by a surprising handful of names. You’ll see it called compactin in older literature, sometimes ML-236B from its discovery days, or occasionally endostatin, though that’s now reserved for a different biological compound. The CAS registry pins it with number 51110-01-1. Individual research suppliers might give it their own catalog codes, but scientists recognize the parent structure behind each synonym. For clarity in the lab, careful reference to chemical name and structure avoids confusion between this early statin and the raft of related molecules developed later.
Handling mevastatin in research lab settings requires gloves, eye protection, and fume hoods. The compound acts as a strong HMG-CoA reductase inhibitor, and accidental dust inhalation or skin contact should be avoided. Lab manuals stress labeling containers clearly and disposing of waste through approved hazardous material systems. Any spill is best managed with absorbent material, double-bagging for disposal, and wiping down surfaces with alcohol. Long-term exposure hasn’t been studied much outside animal models, but the industry treats mevastatin with the same caution reserved for other bioactive fungal metabolites. Regular audits and safety training back up day-to-day chemical hygiene, keeping researchers and their environments in the clear.
Mevastatin transformed the way biologists study cholesterol, providing the first molecular scalpel to dissect metabolic pathways in cells and animals. Researchers use it to block hepatic HMG-CoA reductase, dropping cholesterol synthesis and allowing them to pinpoint downstream effects. In the pharmaceutical sphere, mevastatin stands as the template for new statin development—basically the launch pad for the whole class. Its influence reaches into cardiovascular research, drug screening, natural products chemistry, and cellular biology. Alongside its role in cholesterol science, mevastatin supports structure-activity studies for antifungal and anticancer research, where scientists are still learning whether related compounds have value against diseases other than high cholesterol.
Researchers have spent decades studying mevastatin’s binding properties and tweaking its structure to change pharmacokinetics and toxicity. Early work focused on maximizing reduction of LDL cholesterol without triggering the kinds of muscle, liver, or kidney damage later linked to higher doses and broader statins. More recent efforts look at developing improved analogs with stronger selectivity, rapid breakdown in the body, and minimal off-target effects. Some laboratories study mevastatin as a probe for new targets, illuminating how cholesterol metabolism and synthesis interact with cell growth, immunity, and stress responses. The compound remains a stalwart of preclinical investigation, driving discovery both for heart drugs and for understanding the biology of cholesterol.
Early toxicity testing cast a long shadow over mevastatin’s development. Rats and dogs exposed to high concentrations developed severe muscle and liver damage, signs of rhabdomyolysis and hepatotoxicity that raised alarms for human use. These results steered medical development toward analogs with safer metabolic profiles. Since then, researchers use mevastatin as a yardstick for statin toxicity. Short-term cell culture studies show mitochondrial disruption and altered energy signaling, while chronic dosing in animals uncovers cumulative risk. These insights underscore the care required in dosing, monitoring, and patient selection for statins. Ongoing research explores why some individuals develop complications, hoping to untangle genetic or metabolic markers pointing to risk. Mevastatin’s limitations gave drug developers a reality check and inspired safeguards that shaped statin prescription practices.
The scientific community keeps coming back to mevastatin, both as a research reagent and as a scaffold for new molecules. Synthetic biology advances could pave the way for efficient, green manufacturing of statin analogs, using engineered microbes to produce modified compounds with better properties. In recent years, researchers have looked past cholesterol to see if mevastatin’s core structure might spark new drugs for fungal infections, cancer, or immune disorders. Some are parsing the microbiome’s role in breaking down natural statins or in mediating their effects. Others combine mevastatin-like compounds with nanoparticles or novel delivery vehicles, hoping to reach tissues untouched by current statins. The lessons of this old molecule sit in the foundations of metabolic disease research, and its chemical blueprints will likely shape therapies for years to come.
Few people outside the medical field recognize the name Mevastatin. Doctors and pharmacists see it as a milestone—one of the building blocks of a class of drugs that changed the way we handle cholesterol and reduce heart disease. Some know it as compactin, first discovered in the 1970s from a fungus, Penicillium citrinum. Mevastatin led the way to modern cholesterol-lowering drugs, earning a place in textbooks and research articles.
Cholesterol often gets a bad reputation, and for good reason. Too much of the wrong type, especially low-density lipoprotein (LDL), increases the risk of clogged arteries. Mevastatin stops the enzyme HMG-CoA reductase from making cholesterol in the liver. The drop in cholesterol level sends the liver looking for more, so it pulls more cholesterol out of the bloodstream. Lower cholesterol means lower risk of heart attacks and strokes.
Doctors don’t hand out Mevastatin in pharmacies these days. Other statins, such as Simvastatin and Atorvastatin, are safer and more effective. Even so, Mevastatin’s story matters. Every time a new statin enters the market, its creation follows the same path first cut by Mevastatin. Researchers saw how this old drug could block a single enzyme and deliver a huge payoff for public health.
Scientists still study Mevastatin in the lab. It helps them understand aging, cancer, and inflammation. This kind of research digs into how statins affect other body systems—not just the heart and blood vessels. For example, some studies look at whether blocking cholesterol pathways can slow tumor growth. Results vary, but the data adds new angles doctors may consider one day. The reach of Mevastatin stretches far past its original purpose.
Family members and friends have faced heart attacks; sometimes it felt like a death sentence before statins came along. Lowering cholesterol through diet and exercise helps, but not everyone can reach safe levels that way. Genetics, stress, and other factors sometimes tip the scales no matter how closely someone follows doctor’s orders. Statins give people a fighting chance to stay healthy longer. In my own experience, seeing relatives start statin therapy after a close call felt like hope after panic.
Not every patient should use a statin. Every drug brings risk, including muscle pain or liver effects. Good doctors run blood tests, ask questions, and check that any benefits outweigh possible problems. The lesson of Mevastatin reminds us that no single discovery solves every health problem, but old research keeps teaching us new things.
Medical science learns from every step forward—and the ones that don’t work out the way researchers hoped. Mevastatin led to something better, even if it no longer fills pharmacy shelves. People today have safer statins thanks to scientists who first saw the use of an old fungus in a lab. The story teaches humility and the need for curiosity in every bit of progress, especially when it comes to real lives and real health.
Mevastatin has a job: it works on lowering cholesterol, which scientists see as a big player in the fight against heart attacks and strokes. Before anyone jumps in with both feet, it helps to know what comes with the package. Side effects aren’t just a line in a pamphlet; they show up for real people. My work with patients tells me it’s rare to find someone who takes medication without feeling something in their body shift, whether it’s minor or more worrisome.
People taking statins, including Mevastatin, often talk about muscle soreness. Sometimes it’s a dull ache, sometimes it turns into muscle weakness. A survey from the Cleveland Clinic found that nearly 10% of people on statins deal with muscle pains. Regular headaches can show up too, not always in sync with muscle aches, but often enough for doctors to mention both in the same breath.
Upset stomach, gas, or diarrhea—these issues come up in clinic visits. For many, they pass after a few days, but if stomach pain keeps sticking around, it deserves a fresh look. In some cases, changes in a medical plan or even switching drugs has brought relief to my patients. Good food habits make a difference, though nobody should expect dietary changes to erase all side effects.
Blood tests don’t lie. I’ve seen patients whose test results showed high liver enzymes after starting Mevastatin. That can signal stress on the liver, which isn’t something to brush off. The FDA and guidelines from the American Heart Association say regular blood checks matter, not just when starting treatment but as a watchful routine, especially for people who already juggle other medications.
The JUPITER trial followed this closely—certain people do see a small jump in blood sugar levels on statins, including Mevastatin. Nobody wants a win for cholesterol to turn into new trouble with blood sugar. Multiple studies suggest folks at risk for type 2 diabetes should keep up with regular lab work and open chats with their doctor when starting any type of statin.
Allergic reactions—like rash, itching, or swelling—sound scary because they are. They don’t happen to everyone, but they do come up in emergency room stories. If your breathing feels tight, or your face swells, the only call is to go straight to a hospital. Every statin, Mevastatin included, brings this risk, which raises the flag for anyone starting therapy with a history of allergies.
Small changes help: doctors often suggest starting with the lowest possible dose. Most people tolerate statins better this way. If muscle pain turns up, switching to a different statin sometimes makes a difference. Patients tell me that adding regular walks and a diet rich in leafy greens smooths the transition. Some take breaks under doctor supervision, and many keep a notebook to share details with their healthcare team.
The stories I hear behind closed doors say plenty—nobody wants to trade one health problem for another. Open conversations with healthcare providers can shift outcomes. I’ve seen patients stick to their plan better after they get a clear picture of what symptoms to expect, and what needs medical follow-up. Listening to your own body, and bringing up fresh concerns at each checkup, builds trust and leads to safer, longer lives.
People often want to know the best way to take medicines like mevastatin. More than just a list from the pharmacy, it comes down to simple habits that match daily routines. This statin stands out because it targets cholesterol right at the source, shutting down an enzyme that keeps bad cholesterol high. Doctors prescribe it when diet and lifestyle can't carry the full burden, especially if heart disease or stroke risk looms.
Mevastatin works best when swallowed at the same time each evening, paired with a glass of water. The evening hour isn’t just a ritual—it matches up with the body’s cholesterol production, which climbs overnight. Some might grab dinner late or skip meals, but that routine stays more important than meal timing. Keeping the daily dose on track matters more than tying it to food.
Missed a pill? It happens to everyone. Take it as soon as possible, but not alongside an extra dose. Two at once won't make up for lost time, and stacking pills just piles on risk.
Habits make medicines work. Cholesterol numbers don’t change based on memories alone—they line up with how well instructions are followed. People sometimes start strong but fade off after weeks, as cholesterol issues don’t create the same day-to-day pressure as a bad cold. That’s why cholesterol readings from the doctor matter: they show if mevastatin keeps helping, or if forgetting pills makes those numbers drift in the wrong direction.
Doctors work from more than just a chart. Some bodies react to mevastatin with cramps or liver-related side effects. Trust and communication step in here: blood tests before and during treatment figure out if mevastatin fits well or should be changed. Grapefruit and some other foods can tangle up with how this medicine works, so going over all regular foods, drinks, and supplements during checkups plays a bigger role than most realize.
Fighting off heart disease isn’t just about taking a pill and forgetting about it. Most folks see the best results by mixing this prescription with exercise, smart food choices, and quitting smoking. Stopping suddenly may let cholesterol rebound, placing more stress on the heart. Long-term improvement brings a ripple effect for the whole family—healthy habits stick, and others can take example.
Pillboxes and mobile reminders help many people fall into a stronger pattern. I’ve seen relatives and friends drop their numbers a notch because a calendar alert keeps them on track. Understanding the “why” behind every dose makes the habit meaningful, not just a dry command from the label.
Mevastatin stays safer and works best by matching real life, not complicated science talk or medical jargon. Trusted sources like the American Heart Association share practical guides. Real-world choices keep daily life and long-term health moving in the right direction.
People often don’t realize just how quickly a simple routine—say, taking a cholesterol pill each morning—can become complicated. Mevastatin, part of the statin family, helps keep cholesterol in check, but many folks regularly take more than one medication. Sometimes, adding even a single new pill can throw off the balance, and mevastatin has a few notorious “bad roommates” when it comes to drug interactions.
The liver plays a big part in how mevastatin works. Enzymes there, especially CYP3A4, help break it down. Imagine those enzymes as tiny workers sorting chemicals—any medication that crowds the workroom, like certain antibiotics or antifungals, can slow or jam up the process. Grapefruit juice, for example, blocks those same enzymes, causing mevastatin levels to build up in the body. Some people reach for a glass of juice every morning, not knowing this seemingly healthy habit can raise their risk for muscle pain or even dangerous breakdown of muscle tissue.
Many folks use heart medications, antibiotics, and antifungal pills without thinking twice. Drugs like erythromycin, clarithromycin, and ketoconazole line up as mevastatin troublemakers. They block liver enzymes, making it tough for the body to clear out mevastatin efficiently. Folks might notice symptoms like leg cramps or muscle weakness but connect them to old age or busy days, not a drug clash in their liver. Even antiretroviral medications for HIV or some immunosuppressants have this effect.
Blood thinners, particularly warfarin, deserve extra attention. Mevastatin doesn’t block warfarin directly, but it can increase its effect, making it easier for a person to bruise or bleed. It catches people off guard and, sometimes, even doctors miss the connection until nosebleeds, bleeding gums, or other worrying symptoms arise.
Working at a local pharmacy, I watched people juggle shopping bags and printed prescription papers, often moving fast, wanting to get home—and quick. Some folks didn’t mention herbal supplements, which can also tangle things up. A simple question about grapefruit or a reminder to space out pills often made a real difference. Everyone appreciates clear advice: stay consistent, and call the doctor if something feels off. Experience tells me it’s better to spend two minutes chatting at the counter than ending up with a trip to urgent care.
Open conversations between patients and healthcare providers need more encouragement. Many clinics now use electronic systems that flag dangerous combinations, which helps. Still, not every system covers dietary habits or over-the-counter meds. Patients should keep up-to-date medication lists, right down to vitamins, and bring them to every appointment. Pharmacists and doctors get a full picture this way, catching risks early.
Healthcare providers can also educate about early side effects—muscle pain, dark urine, unexpected bruises—and remind folks not to wait before reaching out. Sometimes changing the timing of pills or swapping to a different statin with fewer interactions makes a significant difference. For the curious, solid resources like the FDA website regularly update known drug interactions, giving patients and providers an extra layer of protection.
Taking mevastatin alongside other medications isn’t always simple, but being mindful keeps people safer. Open communication, reliable resources, and a little time spent double-checking new pharmacy pickups can prevent far bigger problems down the line.
Statins like Mevastatin play a major part in cutting cholesterol and lowering the risk of heart disease. Still, not everyone stands to benefit. Some groups land in a risk zone where taking Mevastatin could bring more harm than help.
People who have chronic liver conditions or a history of liver disease need to stay away from Mevastatin. This medication can add stress to the liver, where it’s processed and broken down. I learned this firsthand from working in a family with a history of hepatitis. A cousin experienced jaundice after trying a statin, only to discover new inflammation in her liver tests. Doctors don’t just make these recommendations lightly — backing comes from long-term safety data and clinical outcomes tracked by drug regulators. Statins like Mevastatin have shown potential to worsen existing liver problems, so regular blood checks become vital for anyone who tries them.
Women who are pregnant or planning to become pregnant need to avoid Mevastatin. Research links statin exposure before and during pregnancy to problems with fetal development, including issues with the heart and nervous system. Breastfeeding mothers shouldn’t take it either. The drug can enter breast milk, passing on risks to a baby whose organs are still developing. Health authorities such as the FDA place Mevastatin among the medications labeled unsafe for pregnant women for exactly these reasons.
Statins sometimes cause muscle pain, weakness, and in rare cases, a serious breakdown of muscle tissue called rhabdomyolysis. People who already have muscle diseases — like myopathy, muscular dystrophy, or a family history of unexplained muscle issues — should approach Mevastatin with real caution. I recall meeting an athlete during physical therapy who had to stop his statin after persistent cramps and weakness. The evidence points to some genetic factors that increase the risk of muscle reactions, and doctors often use lower doses or test for these genes before prescribing.
Mevastatin doesn’t always play well with other medications. Certain antifungals, antibiotics such as erythromycin, and HIV medicines can spike the amount of statin in your blood, increasing the risk of muscle damage or liver troubles. Grapefruit and its juice block enzymes that help break down statins, raising concentrations in ways that catch people off guard. Mixing these can be dangerous, so prescription checks matter more than ever. There’s a real need for people to bring full medication lists to medical appointments.
Older adults, especially those with lots of health conditions or those on several medicines, end up more sensitive to side effects. The odds of muscle pain, memory problems, and falls climb for seniors on Mevastatin. In clinical settings, I’ve seen how one patient’s muscle weakness after a statin prescription led to a series of falls. Careful review can sometimes point to tweaks like lowering the dose or switching the medication altogether.
For people in any of these risk groups, alternatives exist. Better diet, more daily movement, and managing blood sugar or blood pressure can go a long way. Doctors sometimes recommend non-statin cholesterol medicines that don’t hit the liver as hard or trigger muscle breakdown. Open talks with your healthcare provider make all the difference. Honest conversation — and regular blood work — help catch problems before they start.
| Names | |
| Preferred IUPAC name | (3R,5R,6E)-7-(2-(4-hydroxy-6-oxotetrahydropyran-2-yl)ethyl)-3,5-dihydroxyhept-6-enoic acid |
| Other names |
Compactin ML-236B |
| Pronunciation | /miːˈvæstə.tɪn/ |
| Identifiers | |
| CAS Number | 73573-88-3 |
| Beilstein Reference | 1460552 |
| ChEBI | CHEBI:40386 |
| ChEMBL | CHEMBL684 |
| ChemSpider | 14429 |
| DrugBank | DB00635 |
| ECHA InfoCard | 100.120.220 |
| EC Number | EC 1.1.1.34 |
| Gmelin Reference | 86874 |
| KEGG | C08362 |
| MeSH | D008770 |
| PubChem CID | 5282162 |
| RTECS number | OJ0460000 |
| UNII | 9LHU78M5UI |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C23H34O5 |
| Molar mass | 390.507 g/mol |
| Appearance | White, crystalline powder |
| Odor | Odorless |
| Density | 1.15 g/cm3 |
| Solubility in water | slightly soluble |
| log P | 4.71 |
| Vapor pressure | 1.73E-17 mmHg |
| Acidity (pKa) | 4.25 |
| Basicity (pKb) | 15.35 |
| Magnetic susceptibility (χ) | -73.3e-6 cm^3/mol |
| Refractive index (nD) | 1.524 |
| Dipole moment | 4.06 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 502.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -875.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -9371.6 kJ/mol |
| Pharmacology | |
| ATC code | C10AA01 |
| Hazards | |
| Main hazards | May cause mild eye irritation. Dust may cause respiratory irritation. |
| GHS labelling | GHS07; GHS08; Warning; H302; H315; H319; H351 |
| Pictograms | GHWZQ |
| Signal word | Warning |
| Hazard statements | H302 + H332: Harmful if swallowed or if inhaled. |
| Precautionary statements | Keep container tightly closed. Store in a cool, dry place. Avoid breathing dust. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | 110.5 °C |
| Autoignition temperature | 270°C |
| Lethal dose or concentration | LD50 (mouse, oral): >15 g/kg |
| LD50 (median dose) | LD50: 1 g/kg (oral, rat) |
| NIOSH | QU822J8G6N |
| PEL (Permissible) | PEL (Permissible): Not established |
| REL (Recommended) | 0.8 mg |
| Related compounds | |
| Related compounds |
Atorvastatin Cerivastatin Fluvastatin Lovastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin |
